Find in Library

In March 2005, there was outbreak of Polio-1 and expanded throughout Java and Sumatera island. Oral monovalent polio vaccine type 1 (mOPV1) had succeeded in evereeming polio outbreak in Indonesia in 2005. This study aimed to compare neutralizing antibody response to type 1 polio virus in healthy infants receiving either mOPV1 or oral trivalent Polio Vaccine (tOPV), given with other basic vaccination (DTP/HB). Randomized controlled singel blind clinical trial on healthy infants range age 42 to 80 days who had received first oral polio vaccine before 1 month of age. Trial group received mOPV1 and control group tOPV, each had 3 times of vaccination. Blood samples were taken three times (pre vaccination, post second and third vaccination) for measurement of neutralizing antibody to polio virus. Thirty subjects from mOPV1 group and 29 from tOPV group were analyzed. Post second vaccination, mOPV1 group (456) had more increase in geometric mean titer of neutralizing antibody than tOPV group (317) but not significant (p=0.514). Post third vaccination the level of neutralizing antibody titer was almost equal in both groups. Proportion of seroconversion to type 1 polio virus in mOPV1 group 53.9%, 57.7% and tOPV group 25.9%, 41.7% (on second and third evaluation respectively), both were statistically insignificant. Antibody response measured by neutralizing antibody titer and proportion of seroconversion on antibody to type 1 polio virus in healthy infants receiving mOPV1 vaccination was similar to they receiving tOPV.